| INTRODUCTION
Gall bladder mucoceles (GBM) are a leading cause of biliary disease in the dog. 1 A GBM is an accumulation of green-black, tenacious, and immobile bile and mucus that provokes varying degrees of gall bladder distension and biliary duct obstruction. Recent reports of GBM in dogs reflect an increased awareness of the condition and greater availability of abdominal ultrasound 2 but also suggests that this might be an emergent phenomenon. 3 There is breed predisposition to GBM for the Shetland Sheepdog, American Cocker Spaniel, Chihuahua, Pomeranian, and Miniature Schnauzer. 2, 4 The over-representation of particular purebred dogs suggests a genetic contribution to GBM. 5 An insertion mutation in the ABCB4 gene was initially linked to GBM formation in Shetland Sheepdogs 6 but the association was not supported by a later study. Abbreviations: ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; BT, Border terrier; cBT, Border terrier belonging to control group; GBM, gall bladder mucocele; GGT, gamma glutamyltranspeptidase; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; non-BT, other non-border terrier breeds; OR, odds ratio.
The absence of a comparable condition in humans limits our understanding of the pathogenesis of GBMs in dogs. Recognized risk factors for GBM formation include hyperadrenocorticism, hypothyroidism, 8 hyperlipidemia, 4 neonicotinoids, 9 and recently, increased serum leptin. 10 These conditions could act by altering the composition of bile and mucin 11 or through an effect on gall bladder motility. 12 It is likely that multiple mechanisms are involved in GBM development with both genetic and epigenetic factors affecting each predisposed breed. 13 It is our perception that over recent years an increasing number of dogs presenting with GBM have been Border terriers (BT). The number of registrations of BT puppies doubled between 2000 and 2004 and the breed is now established in the top 10 most popular breeds in the United Kingdom. Epileptoid cramping syndrome 14 and a spongiform leukoencephalomyelopathy 15 are in the breed but the BT is not included among predisposed breeds for hypothyroidism, 16 hyperadrenocorticism, 17 diabetes mellitus, 18 or hyperlipidemia. 19 The primary objective of this multicenter, retrospective study was to establish whether there is a breed predisposition for GBM in BT. A second objective was to identify potential breed-specific characteristics relating to risk factors, clinical features, and outcome for the BT by comparing this group to non-BT breeds with GBM. Finally, the incidence of endocrine disease and clinicopathologic abnormalities in BTs was compared directly to a cohort of BTs unaffected by GBM in order to explore potential GBM triggers in the breed.
| MATERIALS AND METHODS
Ethical approval was obtained from the institutional scientific and ethical review committees for each of the participating centers.
Retrospective evaluation of medical records was performed to identify all dogs with an ultrasonographic diagnosis of GBM presenting to Center 1 between January 2010 and September 2017, Center 2 between January 2014 and September 2017 and Center 3 between January 2011 and September 2017. Enrollment criteria included an ultrasonographic diagnosis of GBM determined by specialists in diagnostic imaging according to described criteria (briefly: hypoechoic/ anechoic gall bladder rim and echoic, immobile core of biliary sludge with striated/stellate bands radiating out toward the periphery). 20 Control Border terriers (cBTs) of similar ages to the BTs were sought from each center and were included in the study if they had a complete abdominal ultrasonographic examination with no evidence of GBM. BTs with a description of an early or developing GBM were excluded from the GBM and control groups.
For all GBM cases and cBTs, information recorded, where avail- For purposes of comparison, dogs were grouped as either BT or non-BT. Dogs were also categorized according to whether they underwent cholecystectomy or were managed medically. Dogs that were euthanized without specific treatment for GBM were excluded from this latter comparison.
| Calculations
Cohort selection for breed predisposition calculations was performed according to the method outlined by Aguirre and others. 2 Briefly, the number of dogs seen by a referral clinician (excluding dogs under 2 years of age) with and without GBM and the number of each specific breed (eg, Border terrier) with and without GBM during the time interval of this retrospective study were calculated. Odds ratio (OR) calculations including 95% confidence intervals and p values were performed using an online odds ratio calculator 1 . Breeds in which the 95% confidence interval did not overlap 1.0 were considered to be significantly predisposed to GBM (at the 5% significance level). 
| RESULTS
A total of 64,640 dogs greater than 2 years of age were presented to the three centers over the respective study periods. Of these, Odds ratio are presented for each breed with 95% confidence limits. Breeds displayed in bold typeface have 95% confidence intervals that do not cross 1.0 and are considered predisposed breeds.
with a GBM based on ultrasound alone (34) or ultrasound with histopathologic confirmation (65).
The proportion of dogs presenting with a GBM for each breed to each center are shown in Table 1 .
Of the 51 BTs with GBM, there were 4 (8%) intact males, 18 (35%) neutered males, 6 (12%) intact females, and 23 (45%) neutered females. The BTs had a median age of 9 years 11 months (range 4 years 11 months to 13 years 11 months), and a median bodyweight of 10.0 kg (range 4.9-13.6). The 48 non-BTs with GBM included 9 (19%) intact males, 22 (46%) neutered males, 3 (6%) intact females, and 14 (29%) neutered females. They had a median age of 9 years 1 month (range 2 years 8 months to 15 years 0 month) and median bodyweight of 9.7 kg (range 2.7-37.9). There were no significant differences in age (P = .24), bodyweight (P = .77), sex (P = .044), or neuter status (P = .63) between BTs and non-BTs.
Eighty-seven cBTs that met the inclusion criteria were identified.
The median age of the cBTs was 8 years 8 months (range 1 years 7 months to 15 years 11 months) which was younger than the BT group (P = .037). cBTs were diagnosed with a wide range of different conditions that were broadly grouped into the following categories:
gastrointestinal (n = 29), neurological (16), hepatic/pancreatic (11), oncological (7), renal (7), endocrine (6), cardiorespiratory (4), hematologic (2), orthopedic (2), ophthalmic (1), reproductive (1), or dermato-
The most frequent clinical signs at initial presentation in all 99 dogs with GBM were vomiting (80%), lethargy (70%), inappetence (69%), icterus (35%), abdominal pain (34%), and diarrhea (24%). Table 2 shows a comparison of the frequency of the clinical signs in
BTs and non-BTs. No significant differences in clinical signs were found between these groups.
A total of 24 dogs (4 BTs, 14 non-BTS, and 6 cBTs) were presented with a single previously confirmed endocrinopathy and 5 dogs
(1 BT, 3 non-BTS, and 1 cBT) had been previously diagnosed with two endocrine conditions (Table 3) . Incidence rates for individual endocrinopathies were not significantly different between either the BT and non-BT groups or between BTs and cBTs ( About 56% of dogs (10/18) with GBM tested, had low serum total thyroxine (T 4 ).
Median total bilirubin was significantly greater in BTs than non- Values in bold typeface were significantly different (Bonferroni corrected P value ≤ .0029).
Ten dogs that were not treated specifically for their GBM were censored from the comparison of medically and surgically-managed dogs. About 5 dogs (1 BT, 3 non-BTS and 1 cBT) were diagnosed with two endocrine conditions. 2 dogs (1 BT and 1 non-BT) had hypothyroidism and diabetes mellitus, 2 non-BT had hypothyroidism and hyperadrenocorticism and 1 cBT was diagnosed with hyperadrenocorticism and diabetes mellitus.
1 Enterobacteriacae sp.) and 1/6 non-BTs had a positive culture of gall bladder wall (E. coli); 1/6 liver cultures was positive (Clostridium sp. Three (2 BTs, 1 non-BT) of the 9 dogs that died within 7 days of cholecystectomy had gall bladder rupture identified at surgery. Overall 3/30 dogs with gall bladder rupture died within 7 days which was not significantly different from the 6/59 dogs without gall bladder rupture that died in the same period (P = 1.0) ( Table 6 ).
Of the 12 dogs with an ultrasonographic diagnosis of GBM managed medically, concurrent endocrinopathies were seen in 4/12 dogs (Table 7) ; two additional dogs were alive at the end of the study period but the one-year survival criteria had not yet been reached. There were no significant differences in the proportions of dogs surviving to 7 days, 6 months, or 1 year according to breed status or management approach (Table 7) . Median survival times could not be calculated for any of the groups (<50% case fatality rate).
| DISCUSSION
In this study 99 cases of GBM were identified across three centers.
More than half of these cases were BTs with similar proportions at each site indicating that this is not an issue pertaining to a single location, although might be unique to the United Kingdom. The strongly suspected BT breed predisposition was validated by an OR of 85 (95% confidence interval 56.9-126.8). Odds ratios, by nature of their calculation, tend to overestimate relative risk but, given the low incidence of GBM in all breeds in this study population (compatible with the rare disease assumption), any difference should be minimal. 23 BT 8, 9 and also for gall bladder sludge accumulation. 28 A previous study found that the incidence of diabetes mellitus in GBM cases was not different from the matched control group 8 refuting a role of diabetes mellitus in GBM formation. No differences in the frequencies of individual endocrinopathies was found between BTs and cBTs in our study suggesting that these conditions might not be associated with GBM formation in this breed.
Interestingly, in another study, 56% of cases of hyperadrenocorticism and 45% of hypothyroidism cases were suspected at initial presentation but only confirmed in the 6 months after GBM diagnosis. 8 Due to a lack of detailed follow-up, endocrinopathies diagnosed after GBM diagnosis were not included in our study and any role of endocrine disease in our study might be underestimated.
There were statistically significant differences in the median values of the white blood cells for BTs compared with the cBTs. The median leucocyte, neutrophil, and monocyte counts were greater in BTs while median eosinophil and lymphocyte numbers were lower compared with the cBTs. This combination of differences could represent an exaggeration of the non-specific stress leucogram expected in .022
Mann-Whitney P values for the BT vs non-BT and BT vs cBT comparisons of median values are also shown (MW P value). values in bold typeface were significantly different (Bonferroni corrected P value ≤.0016).
Number of dogs with MCH and MCHC above the reference range not included. .077
Creatinine (mg/dL) .0013
Mann-Whitney P values for the BT vs non-BT and BT vs cBT comparisons of median values are also shown (MW P value). Values in bold typeface were significantly different (Bonferroni corrected P value ≤.0016).
Number of dogs with ALT, ALP, GGT, and AST activities and total bilirubin below the reference range not included.
ill animals due to acute endogenous corticosteroid production. 2 An increased neutrophil count may also reflect the inflammatory response to concurrent cholangitis, cholecystitis, or bile peritonitis.
2,29
Unfortunately, cytological review of a blood smear was inconsistently performed and, thus morphological features of the neutrophils (toxic change, presence of a left shift) were not included in this study.
A higher leucocyte count in dogs with GBM was found in nonsurvivors compared with survivors in two previous studies. 2, 30 However, these findings have not been replicated in other studies 23 and the prognostic value of leucocytosis remains uncertain. While the median neutrophil count of the BTs was significantly higher than the non-BTs in this study there was a greater proportion of non-BTs with neutrophilia. This contradiction limits interpretation of the significance of the higher median neutrophil count in the BTs. Neutrophilic leucocytosis has been associated with bile peritonitis 2 although the incidence of gall bladder rupture was also not different between the groups in our study.
Biochemical findings in both the BTs and non-BTs were similar to those described for dogs with GBM. 1,2,24,27,31 Increased liver serum enzyme activities, particularly ALP and GGT, were seen in greater than 85% cases and this combination of findings is considered highly specific (94%) for hepatobiliary disease. 32 Hyperbilirubinemia was recorded in 65/90 GBM cases but was only manifested as visible icterus in 35/99 cases reflecting the higher optical threshold for clinical icterus. 33 BTs had higher median total bilirubin and were more likely to be hyperbilirubinaemic than non-BTs, potentially reflecting an increased incidence of biliary obstruction/cholestasis, pancreatitis, sepsis, or bacterial cholangitis in this cohort. 29 Cannulation of the common bile duct is commonly performed during cholecystectomy. Cholecystitis occurs in 5%-33% of dogs with GBM 24, 27, 31 and in 80% of Shetland Sheepdogs. 2 The identification of cholecystitis in 11/37 (30%) BTs in this study does not support a primary role for gall bladder inflammation in GBM formation in this breed. Cholangitis was 40 In this study, dogs that underwent cholecystectomy and survived the initial perioperative period had an extended survival time (MST still not reached), in agreement with previous studies. that they were not a healthy cohort. Therefore, despite the lack of ultrasonographic evidence for GBM, any comparison between groups in relation to clinical signs or blood-work abnormalities must be interpreted with caution. The BT and cBT groups were not agematched; the cBT group were younger. This therefore raises the question as to whether some of these cBT would have developed GBM should they have been presented at an older age. As with the previous point, this limits the ability to identify risk factors.
In conclusion, our study provides robust evidence for a predispo- 
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